Company intelligence / Profile preview

Vector Vitale

North Miami Beach, Florida, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~24
Development stage: Other

Overview

Vector Vitale’s lead candidate KLS‑1 is currently in Phase 2 clinical trials for metastatic melanoma. The compound is also under investigation for prostate cancer, pancreatic cancer, CLL, and refractory glioblastoma. KLS‑1 consists of zinc aspartate highly enriched with the stable isotope zinc‑64. Early clinical work focuses on dose finding and safety; efficacy data have not been publicly disclosed.

Therapeutic areas: EndocrinologyOncologyNeurology
Modalities: Small moleculeProtein drugChemical drug
Industry: Biotech

Drug pipeline

2 assets

64Zn-aspartate

1 more asset in the full pipeline.

Request access →

Partnerships

None publicly disclosed.

Beyond the preview

Go deeper on Vector Vitale.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vector Vitale.

Explore the full profile